Background illustration for clinical trials search

Paid Clinical Trials Billings

Discover 125 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for
Non-Small Cell Lung Cancer, NSCLC,
Location: Billings MT, Colorado Springs CO, Grand Island NE,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06162221

Phase1, Phase2, Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

for
Non-small Cell Lung Cancer (NSCLC)
Location: Billings MT, Portland OR, West Haven-Sylvan OR,
Sponsor: Genmab

Sex: All

Age: 18+

Code: NCT07288177

Phase2, Recruiting

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

for
Chemotherapy-induced Nausea and Vomiting
Location: Billings MT, Chandler AZ, Anaheim CA, Skokie IL,
Sponsor: Xiamen LP Pharmaceutical Co., Ltd

Sex: All

Age: 18+

Code: NCT05199818

Phase3, Recruiting

Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer

for
Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8,
Location: Billings MT, Farmington UT, Salt Lake City UT,
Sponsor: NRG Oncology

Sex: Female

Age: 18+

Code: NCT06388018

Phase2, Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

for
DLBCL, Diffuse Large B-Cell Lymphoma
Location: Billings MT, Grand Island NE, Omaha NE, Las Vegas NV,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05139017

Phase2, Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer,
Location: Billings MT, Salt Lake City UT, Aberdeen SD,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06881784

Phase3, Recruiting

Multi-Institutional Registry for Prostate Cancer Radiosurgery

for
Prostate Cancer Early Risk Treated by Radiosurgery,
Location: Billings MT, Great Falls MT, Missoula MT,
Sponsor: RPCR, Inc.

Sex: Male

Age: 18 - 70+

Code: NCT01226004

Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

for
Melanoma Stage IV, Solid Tumor
Location: Billings MT, Scottsdale AZ, San Francisco CA,
Sponsor: Georgiamune Inc

Sex: All

Age: 18+

Code: NCT06425926

Phase1, Phase2, Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

for
Non-small Cell Lung Cancer
Location: Billings MT, Winnipeg, Kansas City MO, Bakersfield CA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06345729

Phase3, Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

for
Advanced Extrapulmonary Neuroendocrine Carcinoma,
Location: Billings MT, Rapid City SD, Salt Lake City UT,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05058651

Phase2, Phase3, Recruiting

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

for
Pancreatic Cancer, Metastatic Pancreatic Cancer,
Location: Billings MT, Salt Lake City UT, Seattle WA, Portland OR,
Sponsor: Astellas Pharma Global Development, Inc.

Sex: All

Age: 18+

Code: NCT07409272

Phase3, Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

for
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Location: Billings MT, Boise ID, Meridian ID, Nampa ID,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04840602

Phase2, Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

for
Colon Adenocarcinoma, Rectal Adenocarcinoma
Location: Billings MT, Ogden UT, Fort Collins CO, Boise ID,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06997497

Phase3, Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

for
CLL, Chronic Lymphocytic Leukemia
Location: Billings MT, Golden CO, Aurora CO, Omaha NE, Eugene OR,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06846671

Phase3, Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

for
Breast Cancer
Location: Billings MT, Seattle WA, Westwood KS, Kansas City MO,
Sponsor: Celcuity Inc

Sex: All

Age: 18+

Code: NCT06757634

Phase3, Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

for
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic,
Location: Billings MT, Spokane WA, Palo Alto CA, Anaheim CA,
Sponsor: Loxo Oncology, Inc.

Sex: All

Age: 18+

Code: NCT05254743

Phase3, Recruiting

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

for
Non-Small Cell Lung Cancer
Location: Billings MT, Sacramento CA, Dallas TX, Austin TX,
Sponsor: BicycleTx Limited

Sex: All

Age: 18+

Code: NCT06933329

Phase2, Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic,
Location: Billings MT, Bozeman MT, Longmont CO, Boulder CO,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07144280

Phase3, Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Billings MT, Spokane WA, Sioux Falls SD, Portland OR,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05947851

Phase3, Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for
Diffuse Large B-Cell Lymphoma
Location: Billings MT, Golden CO, Fargo ND, Edmonton,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06717347

Phase3, Recruiting